Intracranial angioplasty and stenting for cerebral atherosclerosis: a position statement of the American Society of Interventional and Therapeutic Neuroradiology, Society of Interventional Radiology, and the American Society of Neuroradiology. [Society of

info@guidelines.gov (NGC), 2009

National Guideline Clearinghouse | Intracranial angioplasty and stenting for cerebral atherosclerosis: a position statement of the American Society of Interventional and Therapeutic Neuroradiology, Society of Interventional Radiology, and the American Society of Neuroradiology.
Intracranial angioplasty and stenting for cerebral atherosclerosis: a position statement of the American Society of Interventional and Therapeutic Neuroradiology, Society of Interventional Radiology, and the American Society of Neuroradiology.
Intracranial angioplasty and stenting for cerebral atherosclerosis: a position statement of the American Society of Interventional and Therapeutic Neuroradiology, Society of Interventional Radiology, and the American Society of Neuroradiology.
(77343006); (310362005); (418285008); (3258003); (38716007); (55382008); (77477000); (418272005); (372912004); (96302009); (241663008); (90003000); (65818007); (360042007); (30904006); (408463005)
(17-183); (13-469); (16-260); (15-784); (17-461)
Note from the National Guideline Clearinghouse : This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.
Food and Drug Administration (FDA) notified healthcare professionals of updates to the prescribing information concerning interactions between protease inhibitors and certain statin drugs.
Protease inhibitors and statins taken together may raise the blood levels of statins and increase the risk for muscle injury (myopathy).
The most serious form of myopathy, called rhabdomyolysis, can damage the kidneys and lead to kidney failure, which can be fatal.
Food and Drug Administration (FDA) has approved important safety label changes for the class of cholesterol-lowering drugs known as statins.
Information about the potential for generally non-serious and reversible cognitive side effects and reports of increased blood sugar and glycosylated hemoglobin (HbA1c) levels has been added to the statin labels.